公开(公告)号：EP3043815A1

公开(公告)日：2016-07-20

申请号：EP14844704.8

申请日：2014-09-11

申请人： STC.UNM ,  Leidos, Inc.

发明人： PEABODY, David S. ,  CHACKERIAN, Bryce ,  PANNUCCI, James ,  GUTIERREZ, Gabriel M. ,  NOE, Amy Rene ,  WINRAM, Scott Budd ,  HUANG, Steve Chienwen

IPC分类号： A61K39/02 ,  A61K38/16 ,  A61K39/39 ,  A61P31/12

CPC分类号： A61K39/015 ,  A61K35/76 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/55566 ,  C07K2319/40 ,  C12N7/00 ,  C12N15/1037 ,  C12N2795/18122 ,  C12N2795/18123 ,  C12N2795/18134 ,  Y02A50/412

摘要： Embodiments are directed to malaria vaccines comprising a bacteriophage VLP displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.

摘要翻译： 实施方案涉及包含展示通过亲和选择鉴定的异源肽作为抗疟疾模拟表位的噬菌体VLP的疟疾疫苗。

公开(公告)号：EP3104877A1

公开(公告)日：2016-12-21

申请号：EP15708062.3

申请日：2015-02-11

申请人： The USA, as represented by The Secretary, Department of Health and Human Services ,  STC.UNM

发明人： REMALEY, Alan ,  SCHILLERR, John, T. ,  AMAR, Marcelo ,  CHACKERIAN, Bryce

IPC分类号： A61K39/00 ,  C12N9/64 ,  A61P3/06 ,  A61P9/00

CPC分类号： A61K39/0005 ,  A61K38/10 ,  A61K45/06 ,  A61K47/6901 ,  A61K2039/60 ,  A61K2039/627 ,  A61P9/10 ,  C07K11/00 ,  C07K14/47 ,  C12N9/6454 ,  C12N2795/18123 ,  C12N2795/18134 ,  C12N2795/18141 ,  C12Y304/21061

摘要： A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.

摘要翻译： 包含抗原性PCSK9肽和免疫原性载体的疫苗构建体及其使用方法，其有效降低哺乳动物的血液胆固醇水平并且治疗哺乳动物血脂异常和相关疾病状态，而不需要被动免疫策略所需的施用频率 。

公开(公告)号：EP2802349B1

公开(公告)日：2017-12-06

申请号：EP13736349.5

申请日：2013-01-10

申请人： STC.UNM

发明人： CHACKERIAN, Bryce ,  PEABODY, David ,  TUMBAN, Ebenezer

IPC分类号： A61K39/12 ,  C12N7/01 ,  A61P31/20

CPC分类号： A61K39/12 ,  A61K2039/5258 ,  A61K2039/58 ,  C12N2710/20034 ,  C12N2795/18142 ,  C12N2795/18143

摘要： In one aspect, the invention provides immunogenic HPV L2-containing viral-like particles (VLPs). Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. In certain aspects, the VLPs are comprised of a coat polypeptide of the bacteriophages PP7 or MS2, wherein the coat protein is modified by insertion of peptide antigens derived from HPV L2, and wherein the HPV L2 peptide is displayed on the VLP and encapsidates PP7 or MS2 mRNA. Specifically, VLPs of the invention display L2 peptides at the N- terminus of the bacteriophage coat protein. Surprisingly, these L2-displaying VLPs induce more broadly neutralizing antibody responses than when the same peptide is displayed in the AB-loop such that the immunogenic response is enhanced by a factor of at least 10. Immunogenic VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo.

公开(公告)号：EP2519627B1

公开(公告)日：2016-03-30

申请号：EP10841780.9

申请日：2010-12-31

申请人： STC.UNM

发明人： PEABODY, David, S. ,  CHACKERIAN, Bryce

IPC分类号： C12N7/01 ,  C12N15/33 ,  C07K14/005 ,  A61K39/12

CPC分类号： A61K39/12 ,  A61K39/07 ,  A61K2039/5256 ,  A61K2039/5258 ,  C12N7/00 ,  C12N15/1037 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2795/16021 ,  C12N2795/16022 ,  C12N2795/16023 ,  C12N2795/16042 ,  C12N2795/18023 ,  C40B40/08

公开(公告)号：EP3104877B1

公开(公告)日：2020-01-22

申请号：EP15708062.3

申请日：2015-02-11

申请人： The USA, as represented by The Secretary, Department of Health and Human Services ,  STC.UNM

发明人： REMALEY, Alan ,  SCHILLERR, John, T. ,  AMAR, Marcelo ,  CHACKERIAN, Bryce

IPC分类号： A61K39/00 ,  C12N9/64 ,  A61K47/69 ,  A61K38/10 ,  C07K11/00 ,  C07K14/47 ,  A61P3/06 ,  A61P9/00 ,  A61P9/10

公开(公告)号：EP2802349A1

公开(公告)日：2014-11-19

申请号：EP13736349.5

申请日：2013-01-10

申请人： STC.UNM

发明人： CHACKERIAN, Bryce ,  PEABODY, David ,  TUMBAN, Ebenezer

IPC分类号： A61K39/12 ,  C12N7/01 ,  A61P31/20

CPC分类号： A61K39/12 ,  A61K2039/5258 ,  A61K2039/58 ,  C12N2710/20034 ,  C12N2795/18142 ,  C12N2795/18143

摘要： In one aspect, the invention provides immunogenic HPV L2-containing viral-like particles (VLPs). Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. In certain aspects, the VLPs are comprised of a coat polypeptide of the bacteriophages PP7 or MS2, wherein the coat protein is modified by insertion of peptide antigens derived from HPV L2, and wherein the HPV L2 peptide is displayed on the VLP and encapsidates PP7 or MS2 mRNA. Specifically, VLPs of the invention display L2 peptides at the N- terminus of the bacteriophage coat protein. Surprisingly, these L2-displaying VLPs induce more broadly neutralizing antibody responses than when the same peptide is displayed in the AB-loop such that the immunogenic response is enhanced by a factor of at least 10. Immunogenic VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge
in vivo.

公开(公告)号：EP2519627A2

公开(公告)日：2012-11-07

申请号：EP10841780.9

申请日：2010-12-31

申请人： STC.UNM

发明人： PEABODY, David, S. ,  CHACKERIAN, Bryce

IPC分类号： C12N7/01 ,  C12N15/33 ,  C07K14/005 ,  A61K39/12

CPC分类号： A61K39/12 ,  A61K39/07 ,  A61K2039/5256 ,  A61K2039/5258 ,  C12N7/00 ,  C12N15/1037 ,  C12N2710/20022 ,  C12N2710/20034 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2795/16021 ,  C12N2795/16022 ,  C12N2795/16023 ,  C12N2795/16042 ,  C12N2795/18023 ,  C40B40/08

摘要： The present invention relates to a system and method for controlling peptide display valency on virus-like particles (VLPs), especially including MS2 VLPs. In this method, large amounts of wild-type and low quantities of single-chain dimer coat proteins may be produced from a single RNA. Valency is controlled in immunogen (vaccine) production by providing a system that allows the production of large amounts of wild-type and low quantities of single-chain dimer coating proteins from a single RNA, allowing facile adjustment of display valency levels on VLPs, especially MS2 VLPS over a wide range, from few than one-on average—to as many as ninety per particle. This facilitates the production of immunogens and vaccines, including VLPs exhibiting low valency. Nucleic acid constructs useful in the expression of virus-like particles are disclosed, comprised of a coat polypeptide of MS2 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates MS2 niRNA. Nucleic acid constructs are also disclosed which are useful in the expression of virus-like particles comprised of a coat polypeptide of PP7 modified by insertion of a heterologous peptide, wherein the heterologous peptide is displayed on the virus-like particle and encapsidates PP7 mRNA.